MyMedR

Displaying all 4 publications

Abstract:

Sort:

Immediate robot-assisted ureteral reimplantation during robotic prostatectomy in locally advanced prostate cancer

Jung JH, Arkoncel FR, Lee JW, Md Yusoff NA, Hong CH, Hong SJ, et al.

J Robot Surg, 2011 Jun;5(2):149-51.
PMID: 27637544 DOI: 10.1007/s11701-011-0250-2

We report the technique and outcomes of immediate robot-assisted ureteral reimplantation due to unexpected ureteral injury during robot-assisted laparoscopic prostatectomy (RALP). A 61-year-old male was diagnosed with locally advanced prostate adenocarcinoma (T3bN0M0). Multiple positive margins at the bladder neck were noted on frozen section during RALP, and re-excision of the bladder neck was done. Unfortunately, the distal third of right ureter was transected. We immediately performed robot-assisted ureteroneocystostomy with double J stent insertion. No complications developed during the follow-up period.
Birth Cohort Consortium of Asia: Current and Future Perspectives

Kishi R, Zhang JJ, Ha EH, Chen PC, Tian Y, Xia Y, et al.

Epidemiology, 2017 10;28 Suppl 1:S19-S34.
PMID: 29028672 DOI: 10.1097/EDE.0000000000000698

BACKGROUND: The environmental health of children is one of the great global health concerns. Exposures in utero and throughout development can have major consequences on later health. However, environmental risks or disease burdens vary from region to region. Birth cohort studies are ideal for investigating different environmental risks.
METHODS: The principal investigators of three birth cohorts in Asia including the Taiwan Birth Panel Study (TBPS), the Mothers and Children's Environmental Health Study (MOCEH), and the Hokkaido Study on Environment and Children' Health (Hokkaido Study) coestablished the Birth Cohort Consortium of Asia (BiCCA) in 2011. Through a series of five PI meetings, the enrolment criteria, aim of the consortium, and a first-phase inventory were confirmed.
RESULTS: To date, 23 birth cohorts have been established in 10 Asian countries, consisting of approximately 70,000 study subjects in the BiCCA. This article provides the study framework, environmental exposure and health outcome assessments, as well as maternal and infant characteristics of the participating cohorts.
CONCLUSIONS: The BiCCA provides a unique and reliable source of birth cohort information in Asian countries. Further scientific cooperation is ongoing to identify specific regional environmental threats and improve the health of children in Asia.
Fulltext 2019 Seoul Consensus on Esophageal Achalasia Guidelines

Jung HK, Hong SJ, Lee OY, Pandolfino J, Park H, Miwa H, et al.

J Neurogastroenterol Motil, 2020 04 30;26(2):180-203.
PMID: 32235027 DOI: 10.5056/jnm20014

Esophageal achalasia is a primary motility disorder characterized by insufficient lower esophageal sphincter relaxation and loss of esophageal peristalsis. Achalasia is a chronic disease that causes progressive irreversible loss of esophageal motor function. The recent development of high-resolution manometry has facilitated the diagnosis of achalasia, and determining the achalasia subtypes based on high-resolution manometry can be important when deciding on treatment methods. Peroral endoscopic myotomy is less invasive than surgery with comparable efficacy. The present guidelines (the "2019 Seoul Consensus on Esophageal Achalasia Guidelines") were developed based on evidence-based medicine; the Asian Neurogastroenterology and Motility Association and Korean Society of Neurogastroenterology and Motility served as the operating and development committees, respectively. The development of the guidelines began in June 2018, and a draft consensus based on the Delphi process was achieved in April 2019. The guidelines consist of 18 recommendations: 2 pertaining to the definition and epidemiology of achalasia, 6 pertaining to diagnoses, and 10 pertaining to treatments. The endoscopic treatment section is based on the latest evidence from meta-analyses. Clinicians (including gastroenterologists, upper gastrointestinal tract surgeons, general physicians, nurses, and other hospital workers) and patients could use these guidelines to make an informed decision on the management of achalasia.
Long-term outcomes after percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting for left main coronary artery disease: a prospective analysis of the multicentre IRIS-MAIN registry

Wee SB, Kang DY, Ahn JM, Kim JH, Kim MJ, Rha SW, et al.

Lancet, 2026 Nov 03.
PMID: 42976899 DOI: 10.1016/S0140-6736(26)02104-5

BACKGROUND: Percutaneous coronary intervention (PCI) with drug-eluting stents has been widely used to treat patients with left main coronary artery disease; however, long-term comparative outcomes versus coronary artery bypass grafting (CABG) in real-world populations remain poorly characterised. We aimed to compare long-term all-cause mortality after PCI or CABG in Asian patients with unprotected left main coronary artery disease.
METHODS: We analysed prospectively collected data from the multicentre IRIS-MAIN registry, conducted at 46 hospitals in South Korea, India, Japan, Indonesia, and Malaysia. The registry enrolled adults aged 18 years or older with unprotected left main coronary artery disease (defined as a stenosis diameter of ≥50% as visually estimated on angiography), who had been treated with PCI, CABG, or medical therapy alone. The primary outcome was all-cause mortality. We used a target trial emulation framework to compare the long-term risk of all-cause mortality between PCI with drug-eluting stents and isolated CABG. We used propensity-score overlap weighting to adjust for measured baseline covariates. The IRIS-MAIN Registry study is registered with ClinicalTrials.gov (NCT01341327).
FINDINGS: Between Jan 1, 2003, and Dec 31, 2024, 6900 patients were enrolled in the IRIS-MAIN registry, of whom 5379 (78·0%) underwent coronary revascularisation through either PCI with drug-eluting stents (3836 [71·3%]) or CABG (1543 [28·7%]) and were included in the analysis. The median duration of follow-up for all patients was 10·0 years (IQR 5·0-16·7). In the overlap-weighted population, no statistically detectable difference in 10-year weighted Kaplan-Meier rates of all-cause mortality was observed between PCI and CABG (24·0% vs 22·9%; overlap-weighted hazard ratio 1·00 [95% CI 0·87-1·14]; p=0·99). The confidence interval does not exclude a mortality benefit or harm with either strategy.
INTERPRETATION: In this non-randomised registry analysis of patients with left main coronary artery disease, there was no statistically detectable difference in all-cause mortality between PCI and CABG. For patients considered suitable for either strategy, multidisciplinary Heart Team discussion might help patients and clinicians weigh potential trade-offs in the choice between PCI and CABG. These findings are observational and cannot establish causal treatment effects or equivalence in survival.
FUNDING: The CardioVascular Research Foundation (South Korea).